Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

jjay341 Jun. 17 at 7:29 AM

$PPBT imma be ancient if and when this ever moons

0 · Reply

BiotechBonesaw Jun. 17 at 1:08 AM

$TNXP what looks juicier: Tonix, $PPBT , $NUVB , $VKTX , $ALT , or my Jersey Burger for dinner? 🍔 🤤 💪 God bless America 🇺🇸 and help my arteries 🪦 lol

2 · Reply

Stocksavior14 Jun. 16 at 10:10 PM

$PPBT if we had different leadership, maybe. But since we have corrupt management scamming shareholders, probably not

0 · Reply

SirGay_LoveRaw Jun. 16 at 7:49 PM

$PPBT Can we please go ballistic here soon? I mean the stock, just the stock price please...

0 · Reply

StocHolliday Jun. 16 at 7:33 PM

$PPBT me when I see purple executives leaving the parking lot for lunch https://x.com/DogRightGirl/status/1933900615387676735

0 · Reply

G101SPM Jun. 16 at 7:15 PM

#SHOWTIME ^European Association for Cancer Research Congress (June 17) Scheduled to appear: $CGEN, $PPBT ^ GE Aerospace Investor Day (June 17) Scheduled to appear: $GE ^ MercadoLibre, Inc. Annual General Meeting (June 17) Scheduled to appear: $MELI

0 · Reply

LuckyBoy27 Jun. 16 at 5:21 PM

$PPBT

0 · Reply

JamesPond007 Jun. 16 at 4:20 PM

$PPBT

0 · Reply

Dr_HIM Jun. 16 at 3:49 PM

$PPBT 👀($2.50)👀

1 · Reply

BiotechBonesaw Jun. 16 at 3:32 PM

$PPBT CM24 & NT-219 are game changers… when will $BMY or $MRK sign a deal to extend their Immunooncology dominance? $RHHBY could use a win too after the unfortunate setback in DMD by Sarepta $SRPT

0 · Reply

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 5 weeks ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 7 weeks ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 3 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 4 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 6 months ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 6 months ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 7 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 7 months ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 8 months ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 8 months ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 8 months ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 9 months ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 10 months ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 10 months ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 11 months ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 1 year ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 1 year ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 1 year ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 1 year ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Feb 14, 2023, 7:01 AM EST - 2 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Feb 8, 2023, 7:12 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Nov 15, 2022, 7:00 AM EST - 2 years ago

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Nov 8, 2022, 7:53 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2022 Financial Results

Nov 2, 2022, 7:37 AM EDT - 2 years ago

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Aug 4, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2022 Financial Results

Jul 14, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Announces Executive Leadership Changes

May 27, 2022, 7:15 AM EDT - 3 years ago

Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

May 18, 2022, 8:18 AM EDT - 3 years ago

Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients

jjay341 Jun. 17 at 7:29 AM

$PPBT imma be ancient if and when this ever moons

0 · Reply

BiotechBonesaw Jun. 17 at 1:08 AM

$TNXP what looks juicier: Tonix, $PPBT , $NUVB , $VKTX , $ALT , or my Jersey Burger for dinner? 🍔 🤤 💪 God bless America 🇺🇸 and help my arteries 🪦 lol

2 · Reply

Stocksavior14 Jun. 16 at 10:10 PM

$PPBT if we had different leadership, maybe. But since we have corrupt management scamming shareholders, probably not

0 · Reply

SirGay_LoveRaw Jun. 16 at 7:49 PM

$PPBT Can we please go ballistic here soon? I mean the stock, just the stock price please...

0 · Reply

StocHolliday Jun. 16 at 7:33 PM

$PPBT me when I see purple executives leaving the parking lot for lunch https://x.com/DogRightGirl/status/1933900615387676735

0 · Reply

G101SPM Jun. 16 at 7:15 PM

0 · Reply

LuckyBoy27 Jun. 16 at 5:21 PM

$PPBT

0 · Reply

JamesPond007 Jun. 16 at 4:20 PM

$PPBT

0 · Reply

Dr_HIM Jun. 16 at 3:49 PM

$PPBT 👀($2.50)👀

1 · Reply

BiotechBonesaw Jun. 16 at 3:32 PM

$PPBT CM24 & NT-219 are game changers… when will $BMY or $MRK sign a deal to extend their Immunooncology dominance? $RHHBY could use a win too after the unfortunate setback in DMD by Sarepta $SRPT

0 · Reply

Smittysixty Jun. 16 at 1:58 PM

$PPBT quietly playing chess, not checkers… 🧬 Highlighting CAPTN-3 at #EACR2025 for scientific credibility, but no mention of #BIO2025 in their PR. Yet they’re confirmed on the BIO attendee list. With < $8M cash and 3 assets needing serious funding to advance, this silent BIO presence feels very strategic. Eyes on business development moves. 👀 Of course, the FUD squad stays loud and intentionally clueless… but stealth at BIO tells a different story……

0 · Reply

Stocksavior14 Jun. 16 at 12:02 PM

$PPBT more silence and more dilution…. The permabulls favorite

1 · Reply

purpdaddy Jun. 16 at 10:30 AM

$PPBT what is going on this week that is bullish?

2 · Reply

TOOKPROFITS Jun. 16 at 6:35 AM

$PPBT wens next RS Itzick

0 · Reply

BiotechBonesaw Jun. 16 at 2:42 AM

$PPBT not just Purple Biotech. $ALT $AKRO $TNXP $SMMT all ripe for deals amongst others🧐

0 · Reply

Kevin73ca Jun. 16 at 12:35 AM

$JFBR $KPTI $NVCR $PPBT What’s that meaning

0 · Reply

eyal10 Jun. 15 at 8:23 PM

$PPBT last night an iranian ballistic missile hit weizman institute in rehovot , very close to purple office.

4 · Reply

Oxinternet Jun. 15 at 7:45 PM

$PPBT If Izzy wants to give me back the £55,000 he stole from, I’ll put an Israel flag in my bio 🤣

0 · Reply

BiotechBonesaw Jun. 15 at 6:40 PM

$JFBR rumor is they’re going after short sellers of their companies next 🤯 $KPTI $NVCR $PPBT

1 · Reply

Randy_Lahey_Trevor_Corey Jun. 14 at 7:42 PM

$PPBT the winds of shit

1 · Reply

Smittysixty Jun. 14 at 5:42 PM

$PPBT Purple’s executive team is heading into the year’s biggest bio-investor conference armed with NT-219 data from a trial that wrapped up over a year ago. That’s some pretty mature phase 1/2 data—one has to wonder how many of those patients are still alive and thriving. We’re not exhibiting, so it’s likely that this groundbreaking data is being reserved for private one-on-one meetings. If any details leak to journalists, we could see some serious trading activity. Let’s see what unfolds during and after the conference. Personally, I’m pretty excited.

1 · Reply

StocHolliday Jun. 14 at 2:51 PM

$PPBT this stock has an iron dome against price increases

1 · Reply

Market Cap	3.26M
Revenue (ttm)	0.00
Net Income (ttm)	-7.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,800
Avg Vol	130,208
Day's Range	N/A - N/A
Shares Out	1.33M
Stochastic %K	20%
Beta	0.50
Analysts	Strong Sell
Price Target	$34.00